The CYP2D6 extensive metabolizer genotype is associated with increased risk for bladder cancer

Cancer Letters

Volumn 119, Issue 1, 1997, Pages 115-122

  Abdel Rahman, Sherif Z ^a   Anwar, Wagida A ^b   Abdel Aal, Wafaa E ^c   Ghoneim, Magdy A ^d   Au, William W ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b AIN SHAMS UNIVERSITY   (Egypt)

^c NATIONAL RESEARCH CENTRE   (Egypt)

^d Cairo University   (Egypt)

Author keywords

Bilharzia; Bladder cancer; CYP2D6; Cytochrome P 450 schistosoma; Genetic polymorphism; Genetic susceptibility; PCR; RFLP

Indexed keywords

CYTOCHROME P450;

ARTICLE; BLADDER CANCER; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; EGYPT; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHISTOSOMIASIS; SMOKING; SQUAMOUS CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CARCINOMA, TRANSITIONAL CELL; CYTOCHROME P-450 CYP2D6; EGYPT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK FACTORS; SCHISTOSOMIASIS; URINARY BLADDER NEOPLASMS;

EID: 0030695418     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(97)00265-6     Document Type: Article

References (52)

1. J. Higginson, C.S. Muir, N. Munoz, Human Cancer: Epidemiology and Environmental Causes, Cambridge University Press, Cambridge, 1992.
2. S.A. Ibrahim, Site distribution of cancer in Egypt. Twelve years experience (1970-1981), in: M. Kogali, Y.T. Omar, A. Gjorgov, A.S. Ismail (Eds.), Cancer Prevention in Developing Countries, Pergamon Press, Oxford, 1986, pp. 45-50.
3. J.M. Harrington, R. Saracci, Clinical and epidemiological aspects, in: P.A.B. Raffle, P.H. Adams, P.J. Baxter, W.R. Lee (Eds.), Hunter's Diseases of Occupations, eighth ed., Edward Arnold, London, 1994, pp. 654-688.
4. World Health Organization, The Epidemiological Association between Schistosoma haematobium infection and bladder cancer. Technical Report Series No. 186.86, WHO, Geneva, 1986.
5. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 61. Schistosomes, Liver Flukes and Helicobacter pylori, International Agency for Research on Cancer, Lyon, 1994, pp. 45-119.
6. M.N. El-Bolkainy, N.M. Mokhtar, M.A. Ghoneim, M.H. Hussein, The impact of schistosomiasis on the pathology of bladder carcinoma, Cancer 48 (1981) 2643-2648.
7. M.G. Chen, K.E. Mott, Progress in assessment of morbidity due to Schistosoma haematobium infection. A review of recent literature, Trop. Dis. Bull. 86 (1989) R1-R36.
8. R.M. McCully, C.N. Baron, A.W. Cheever, Schistosomiasis (Bilharziasis), in: C.H. Bindford, D.H. Connor (Eds.), Pathology of Tropical and Extraordinary Diseases, Armed Forces Institute of Pathology, Washington, DC, 1986. pp. 428-508.
9. D. Kamel, Y. Soini, K. Nuorva, A. Khalifa, A. Mangoud, K. Vahakangas, P. Paakko, p53 and c-erbB-2 expression in schistosomal urinary bladder carcinomas and schistosomal cystitis with premalignant lesions, Virchows Arch. 424 (1994) 349-355.
10. W. Warren, P.J. Biggs, M.A. Ghoneim, M.R. Stratton, S. Venitt, Mutations in the p53 gene in schistosomal bladder cancer: a study of 92 tumors from Egyptian patients and a comparison between mutational spectra from schistosomal and non-schistosomal urothelial tumors. Carcinogenesis 16 (1995)1181-1189.
11. W.S. El-Masri, G. Fellows, Bladder cancer after spinal cord injury. Incidence, presentation, histology and prognosis compared with bladder cancer in the non-paralyzed popu-lation, Paraplegia 19 (1981) 265-270.
12. A.F. Kantor, P. Hartge, R.N. Hoover, A.S. Narayana, J.W. Sullivan. J.F. Fraumeni Jr., Urinary tract infection and risk of bladder cancer, Am. J. Epidemiol. 19 (1984) 510-515.
13. P.J. Dolin, S.C. Darby, V. Beral, Paraplegia and squamous cell carcinoma of the bladder in young women: findings from a case-control study, Br. J. Cancer 70 (1994) 167-168.
14. F.P. Guengerich, Characterization of the roles of human cytochrome P450 enzymes in carcinogen metabolism. Asia Pacific J. Pharmacol. 5 (1990) 327-345.
15. D.W. Nebert, Polymorphism of human CYP2D6 genes involved in drug metabolism: possible relationship to individual cancer risk, Cancer Cell 3 (1991) 93-96.
16. J. Idle, Is environmental carcinogenesis modulated by host polymorphism?, Mutat. Res. 247 (1991) 259-266.
17. A. Rannung, A. Alexandrie, I. Persson, M. Ingelman-Sundberg, Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1 : regulation and toxicological signifi-cance, J. Occup. Environ. Med. 37 (1995) 25-36.
18. C.F. Meyer, U.M. Zanger, D. Grant, M. Blume, Genetic polymorphism of drug metabolism, Adv. Drug Res. 19 (1990) 198.
19. O. Pelkonen, D.D. Breimer, Role of environmental factors in the of drugs-considerations on animal models. P450 enzymes and probe drugs, in: P.G. Welling, L.P. Balant (Eds.), Hand-book of Experimental Pharmacology, Pharmacokinetics of Drugs, Vol. 110, 1994, pp. 289-332.
20. A.K. Daly, J. Brockmöller, F. Broly, M. Eichelbaum, W.E. Evans, F.J. Gonzalez, J.D. Huang, J.R. Idle, M. Ingelman-Sundberg, T. Ishizaki, E. Jacqz-Aigrain, U.A. Meyer, D.W. Nebert, V.M. Steen, C.R. Wolf, U.M. Zanger, Nomenclature for human CYP2D6 alleles, Pharmacogenetics 6 (1996) 193-201.
21. M. Heim, U.A. Meyer, Genotyping poor metabolizers of debrisoquine by allele-specific PCR amplification, Lancet 336 (1990)529-532.
22. A.C. Gough, J.S. Miles, N.K. Spurr, J.E. Moss, A. Gaedigk, M. Eichelbaum, C.R. Wolf, Identification of the primary gene defect at the cytochrome P450 CYP2D6 locus, Nature 347 (1990)773-776.
23. M. Kagimoto, M. Heim, K. Kagimoto, T. Zeugin, U. Meyer, Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrizoquine, J. Biol. Chem. 265 (1990) 17209-17214.
24. A. Gaedigk. M. Blum, R. Gaedigk, M. Eichelbaum, U.A. Meyer, Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism, Am. J. Hum. Genet. 48 (1991) 943-950.
25. 1934-A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site, Am. J. Hum. Genet. 47 (1990) 994-1001.
26. N. Caporaso, M.T. Landi, P. Vineis, Relevance of metabolic polymorphism to human carcinogenesis: evaluation of epidemiologic evidence, Pharmacogenetics 2 (1991) 4-19.
27. L. Roots, J. Brokmöller, N. Drakoulis, R. Loddenkemper, Mutant genes of cytochrome P-450IID6, glutathione S-transferase class mu and arylamine N-acetyltransferase in lung cancer patients, J. Clin. Invest. 70 (1992) 307-319.
28. A. Hirvonen, K. Husgafvel-Pursiainen, S. Anttila, A. Karjalainen, O. Pelkonen, H. Vainio, PCR-hased CYP2D6 genotyping for Finnish lung cancer patients, Pharmacogenetics 3 (1993) 19-27.
29. J.A.G. Agundez, C. Martinez, J.M. Lardero, M.C. Ledesma, J.M. Ramos, R. Martin, A. Rodriquez, C. Jara, J. Benitez, Debrisoquin oxidation genotype and susceptibility to lung cancer, Clin. Pharmacol. Ther. 55 (1994) 10-14.
30. C.R. Wolf, C.A.D. Smith, A.C. Gough, J.E. Moss, K.A. Vallis, G. Howard, F.J. Carey, K. Mills, W. McNee, J. Carmichael, N.K. Spurr, Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility, Carcinogenesis 13 (1992) 1035-1038.
31. T. Tefre, A.K. Daly, M. Armstrong, J.B.S. Leathsrt, J.R. Idle, A. Brogger, A.-L. Borrensen, Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls, Pharmacogenetics 4 (1994) 47-57.
32. A. Kaisary, P. Smith. C. Jaczq, C.B. McAllister, G.R. Wilkinson, W.A. Ray, R.A. Branch, Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors, Cancer Res. 47 (1987) 5488-5493.
33. C.M. Fleming, A. Kaisary, G.R. Wilkinson, R.A. Branch, The ability to 4-hydroxylate debrisoquine is related to recurrence of bladder cancer, Pharmacogenetics 2 (1992) 128-134.
34. R.A. Persad, C.M. Fleming, G.R. Wilkinson, P.J. Smith, R.A. Branch, Bladder cancer recurrence and its association with cytochrome P450 2D6 activity, Prog. Clin. Biol. Res. 378 (1992) 19-27.
35. W.A. Anwar, S.Z. Abdel-Rahman, R.A. El-Zein, W.W. Au, Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients, Carcino-genesis 17 (1996) 1923-1927.
36. F.K. Mostofi, L.H. Sobin, H. Torloni, Histologic typing of urinary bladder tumors, International Histological Classification of Tumors, Vol. 10, World Health Organization, Geneva, 1973.
37. 14C]acrylonitrile with DNA in gastric tissue of rat, J. Biochem. Toxicol. 9 (1994) 191-198.
38. N. Spurr, A.C. Cough, D. Smith, R. Wolf, Genetic analysis of cytochrome P450 system, Methods Enzymol. 206 (1991) 149-166.
39. N.E. Breslow, N.E. Day, Statistical Methods in Cancer Research, Vol. I, International Agency for Research on Cancer, Lyon, 1980.
40. J.A.G. Agundez, C. Martinez, M.C. Ledesma, M.G. Ladona, J.M. Ladero, J. Benitez, Genetic basis for differences in debrisoquin polymorphism between Spanish and other white populations, Clin. Pharmacol. Ther. 55 (1994) 412-417.
41. F. Broly, A. Gaedigk, M. Heim, M. Eichelbaum, K. Morike, U.A. Meyer, Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in European population, DNA Cell Biol. 10 (1991) 545-558.
42. J.A. Agundez, M.C. Ledesma, J. Benitez, J.M. Ladero, A. Rodriguez-Lescure, E. Diaz-Rubio, M. Diaz-Rubio, CYP2D6 genes and risk of liver cancer, Lancet 345 (1995) 830-831.
43. N.K. Spurr, A.C. Gough, F.I. Chinegwundoh, C.A. Smith, Polymorphisms in drug-metabolizing enzymes as modifiers of cancer risk, Clin. Chem. 41 (1995) 1864-1869.
44. J. Brokmöller, I. Cascorbi, R. Kerb, I. Roots, Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases Ml and Tl, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk, Cancer Res. 56 (1996) 3915-3925.
45. R.A. El-Zein, J.B. Zwischenberger, S.Z. Abdel-Rahman, A.B. Sankar, W.W. Au, Polymorphism of metabolizing genes and lung cancer histology: prevalence of CYP2E1 and adenocarcinoma, Cancer Lett. 112 (1996) 71-78.
46. S.Z. Abdel-Rahman, W.A. Anwar, W.E. Abdel-Aal, H.M. Mostafa, W.W. Au, GSTM1 and GSTT1 genes are potential risk modifiers for bladder cancer. Cancer Detect. Prev., in press.
47. C.L. Crespi, B.W. Penman, H.V. Gelboin, F.J. Gonzalez, A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-l-(3-pyridyl)-l-butanone, is activated by multiple human cytochrome P450s including the polymorphic human P4502D6, Carcinogenesis 12 (1991) 1197-1201.
48. B.W. Penman, J. Reece, T. Smith, C.S. Yang, H.V. Gelboin, F.J. Gonzalez, C.L. Crespi, Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6, Pharmacogenetics 3 (1993) 28-39.
49. C.L. Crespi, D.T. Steimel, B.W. Penman, K.R. Korzekwa, P. Femandez-Salguero, J.T. Buters, H.V. Gelboin, F.J. Gonzalez, J.R. Idle, A.K. Daly, Comparison of substrate metabolism by wild type CYP2D6 protein and a variant containing methionine, not valine, at position 374, Pharmacogenetics 5 (1995) 234-243.
50. R.M. Hicks, Nitrosamines as possible etiological agents in bilharzial bladder cancer, in: P.N. Magee (Ed.), Banbury Report No. 12: Nitrosamines and Human Cancer, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1982, pp. 455-471.
51. A.R. Tricker, B. Spielhader, R. Preussman, Environmental exposure to preformed N-nitroso compounds and nitrosating agents in human cancer etiology, Pharmacogenetics 2 (1989) 272-277.
52. M.H. Mostafa, S. Helmi, A.F. Badawi, A.R. Tricker, B. Spiegelhalder, R. Preussmann, Nitrate, nitrite and volatile nitroso compounds in the urine of Schistosoma haematobium and Schistosoma mansoni infected patients, Carcinogenesis 15 (1994) 619-625.